medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2022, Number 03

<< Back Next >>

Ginecol Obstet Mex 2022; 90 (03)

Ovarian borderline tumor: Review of an old acquaintance with new therapeutic proposals

Novoa-Vargas A, Contreras-Álvarez J, García-Escorcia E

Language: Spanish
References: 39
Page: 261-272
PDF size: 660.92 Kb.


ABSTRACT

Background: Patients with borderline ovarian tumor can be treated conservatively in early stages and thereby achieve considerable survival. Advanced stages have a prolonged disease-free period, some with peritoneal implant growth and relapse after 10 years of treatment.
Objective: To know the prognosis of patients with borderline ovarian tumor and its treatment in Mexico and other countries.
Methodology: Systematic review of recent clinical trials registered in PubMed, Embase and Cochrane databases of articles published in English and Spanish between 2006 and 2021. In addition, an analytical review of the experience accumulated in 10 years in the care of patients with borderline ovarian tumor attended at the Oncology High Specialty Medical Unit of the XXI Century National Medical Center of the Mexican Social Security Institute, in Mexico City and other medical centers in the Mexican Republic.
Results: We found 62 articles related to the search terms; of these, 11 were discarded because they were not original articles only on ovarian borderline tumors and 4 because the full text was written in languages other than English and Spanish. One more was eliminated because its conclusions differed from the stated objective and its support was considered weak. In the end, 41 articles were analyzed.
Conclusions: The chances of surgical care of patients with ovarian borderline tumor, with fertility preservation, are high because its recurrence is low. Mucinous microinvasive tumors, with vascular and lymphatic permeation, will have a higher chance of long-term relapse. In general, their prognosis for survival, at each stage, is high. Retroperitoneal lymphadenectomy is not indicated in early stages of the disease.


REFERENCES

  1. Taylor HC. Malignant and semimalignant tumors of the ovary. Surg Gynecol Obstet 1929; 48: 204-30.

  2. International Federation of Gynecology and Obstetrics Classification and staging of malignant tumors in the female pelvis. Acta Obstet Gynecol Scand 1971; 50:1-7.

  3. Kleppe M, Bruls J, Van Gorp T y cols. Mucinous borderline tumours of the ovary and the appendix: A retrospective study and overview of the literature. Gynecol Oncol 2014; 133: 155-8. https://doi.org/10.1016/j.ygyno.2014.02.013

  4. Kavak Comert D, Ureyen I, Karalok Alper et al. Mucinous borderline ovarian tumors: Analysis of 75 patients from a single center. J Turk Ger Gynecol Assoc 2016; 17: 96-100. doi: 10.5152/jtgga.2016.15208

  5. Carter J, et al. Borderline and invasive epithelial ovarian tumors in young women. Obstet Gynecol 1993; 82: 752. PMID: 8414321

  6. Zapardiel I, Rosednberg P, Peiretti M, Zanagnolo V, Sanguineti F, Aletti G. The role of restaging borderline ovarian tumors: Single experience and review of the literature. Gynecol Onco 2010; 119: 274-7. https://doi.org/10.1016/j.ygyno.2010.07.034

  7. Torres-Lobatón A, Morgan-Ortiz F. Tumores limítrofes de ovario, experiencia de 50 casos. GAMO 2016; 15 (2): 70-77. https://doi.org/10.1016/j.gamo.2015.12.012

  8. Gershenson DM. Clinical management potential tumours of low malignancy. Best Pract Res Clin Obstet Gynaecol 2002; 16: 513-27. https://doi.org/10.1053/beog.2002.0308

  9. Kosbell M, Bell D, Carcangui M et al, Sero-mucinosus tumours, WHO Classification IARC, Lyon 2014; 38-40.

  10. Maeda D, Shih IM. Pathogenesis and the role of ARIDIA mutation in endometriosis-related ovarian neoplasms. Adv. Anat. Pathol 2013; 20: 45-52. doi: 10.1097/PAP.0b013e31827bc24d

  11. Disaia PJ, et al. Oncologia Ginecológica Clínica en Tumores anexiales. Elsevier, 2018: 245-52.

  12. Shin KH, et al. Clinical Usefulness of Cancer Antigen (CA) 125, Human Epididymis 4, and CA72-4 Levels and Risk of Ovarian Malignancy Algorithm Values for Diagnosing Ovarian Tumors in Korean Patients With and Without Endometriosis. Ann Lab Med 2020; 40: 40-47. https://doi.org/10.3343/alm.2020.40.1.40

  13. Jacobs I. Steady, relentless progress towards effective, safe screening for early detection of cancer of the ovary. BJOG 2018; 125: 526-29. doi: 10.1111/1471-0528.14830

  14. Kavak Cömert et al. Analyzing of mBOTs. J Turk Ger Gynecol Assoc 2016; 17: 96-10.

  15. Qing W, Yu D, Fang W. Clinical and computed tomographic features of ovarian lesions in infants, children, and adolescents: A series of 222 cases. Pediatr Adolesc Gynecol 2021; (34): 387-93. https://doi.org/10.1016/j.jpag.2020.10.007

  16. Sun L, N Li, Song Y, et al. Clinicopathologic features and risk factors for recurrence of mucinous borderline ovarian tumors. A retrospective study with follow-up of more than 10 years. International J of Gynecological Cancer 2018; 28 (9): 1643-49.

  17. Nyangoh Krystel, Bendifallah Sofiane, Lobna Dion. Gynecolgie Obstetrique Fertilié and Sénologie. 2020; 01: 23-25.

  18. Tsilidis K, Allen NE, Key TJ, Dossus L, Lukanova A, Bakken K, et al. Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition. Br J Cancer. 2011; 105 (9): 1436-42. doi:10.1038/bjc.2011.371

  19. Sánchez-Lander J y col. Rev Venez Oncol 2014; 26 (3): 235-92.

  20. Hart William. Modern Pathology 2005(18): S33-S50

  21. JNCCN.org 2021;19(2):191-225

  22. Chen Rui-fang, Li Jun, Zhu Ting-ting, et al. Fertility-sparing surgery for young patients with borderline ovarian tumors (BOT´s): single institution experience. J Ovarian Res 2016; 9 (9): 2-8. https://doi.org/10.1186/s13048-016-0226-y

  23. Gershenson DM. Management of borderline ovarian tumours. Obstetrics and Gyneacology 2017; 41: 49-59. https://doi.org/10.1016/j.bpobgyn.2016.09.012

  24. Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. A Cancer J Clin 2011; 61: 183-203. https://doi.org/10.3322/caac.20113

  25. Della Pepa Ch, Tonini G, Santini D, et al. Low grade serous ovarian carcinoma: From the molecular characterization to the best therapeutic strategy. Cancer Treatment Rev 2015; 41 (2): 136-43. https://doi.org/10.1016/j.ctrv.2014.12.003

  26. Malpica A, KK. The molecular pathology of ovarian serous borderline tumors. Ann Oncol 2016 Suppl 27: i16-i19. doi: 10.1093/annonc/mdw089

  27. Sánchez-Lander J, Loreta-Di-Giampietro F, Medina E, et al. Primer consenso nacional de cáncer epitelial de ovario diagnóstico y tratamiento. Rev Venez Oncol 2014; 26 (3): 235-92.

  28. Schorge JO, Modesitt SC, Coleman RL, Cohn DE, Kauff ND, Duska LR, et al. SGO White paper on ovarian cancer: Etiology, screening and surveillance. Gynecol Oncol 2010; 119 (1): 7-17. doi:10.1016/j.ygyno.2010.06.003

  29. Ohnishi, K., Nakayama, K., Ishikawa, M. et al. Mucinous borderline ovarian tumors with BRAFV600E mutation may have low risk for progression to invasive carcinomas. Arch Gynecol Obstet 302, 487-495 (2020). https://doi.org/10.1007/s00404-020-05638-8

  30. Sun Li, MD et al. Int J Gynecol Cancer 2018;28: 1643-1649

  31. Giorgini Margherita,y cols. Limits of 18F-Fluorodeoxyglucose Positron Emission Tomography in Recurrence Diagnosis of Borderline Ovarian Tumor. Int J Gynecol Cancer 2010;20: 694-697

  32. Camarillo E, Quezada AE. Incidencia de metástasis ganglionares en tumores de ovario limítrofes en el H de Oncología CMN, Siglo XXI. IMSS. Mar 2016

  33. Gallardo-Rincón D, Cantú de León D, Alanís-López P y cols. GAMO 2011; 63; 6: 665-701.

  34. Russell Vang, Charlotte G Hannibal, Jette Junge, et al. Am J Surg Pathol. 2017 Jun; 41 (6): 725-737. doi: 10.1097/ PAS.824

  35. McKenney JK, Balzer BL, Longacre TA. Los Patrones de invasión estromal en tumores serosos ováricos de bajo potencial maligno (tumores límite): una reevaluación del concepto de microinvasión estromal. J Surg Pathol. Octubre de 2006; 30 (10): 1209-21. doi: 10.1097 / 01.pas.213299.11649.fa.

  36. Kumari Sarita, Kumar Sunesh, BhatlaNeerja et al. Oncologic and reproductive outcomes of borderline ovarian tumors in Indian population. Gynecol Oncol reports2021;(36):1-7.

  37. Shih Ie-Ming y Kurman Robert J. Clin Cancer Res 2005;11:7273-7279.

  38. Debora K, Amstrong, Alvarez Ronal D, et al. NCCN.Clinical practice guidelines in Oncology. 2021;19(2):191-226.

  39. Gerd Hannibal Ch, Kurman, Susanne K Kjaer . A Nationwide Study of Ovarian Serous Borderline Tumors in Denmark 1978-2002. Risk of Recurrence, and Development of Ovarian Serous Carcinoma. Gynecol Oncol. 2017 Jan;144(1):174-180. doi: 10.1016/j.ygyno.2016.11.007.




2020     |     www.medigraphic.com